Gaorong Capital and Yunfeng Capital led a $200m Series B funding round in Sironax.

Gaorong Capital, a venture capital company, and Yunfeng Capital, a private equity investment services, led a $200m Series B funding round in Sironax, a developer of pharmaceuticals for inflammatory and neuro-degenerative diseases, with participation from Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners, K2 Venture, MSA Capital, CBC Group, Long River Investments, LSV Capital, Superstring Capital, Future Innovation Fund and Abu Dhabi Investment Authority. "We are pleased to be supported by a syndicate of leading investors to enable us to achieve our vision of bringing transformational therapies to patients around the globe whose lives are impacted by a broad range of degenerative diseases. Building upon groundbreaking discoveries—including many by our co-founder Dr. Xiaodong Wang—we have built a robust pipeline of novel programs of both small molecules and biologics that target critical pathways underlying degenerative disease pathogenesis. With this investment, we are well-positioned to advance additional programs into the clinic and continue to move our lead program forward," Aaron Ren, Sironax CEO.